| CXCR7 primary tumor (ESCC) |  | ||||||
---|---|---|---|---|---|---|---|---|
 | Total | CXCR7 negative | CXCR7 positive | p-value | ||||
 |  | (n=87, 55%) | (n=72, 45%) |  | ||||
Median Age, years (range) | 159 | 60.9 | (36–80) | 62.1 | (37–93) | 0.158 | ||
Sex | Â | Â | Â | Â | Â | Â | Â | |
 | Female | 119 | 70 | (59%) | 49 | (41%) |  | |
 | Male | 40 | 17 | (43%) | 23 | (57%) | 0.098 | |
Disease Stage (UICC 7th edition) | Â | Â | Â | Â | Â | Â | ||
 | T | 1 | 23 | 15 | (65%) | 8 | (35%) |  |
 |  | 2 | 33 | 18 | (55%) | 15 | (45%) |  |
 |  | 3 | 91 | 47 | (52%) | 44 | (48%) |  |
 |  | 4 | 12 | 7 | (58%) | 5 | (42%) | 0.698 |
 | N | 0 | 67 | 36 | (54%) | 31 | (46%) |  |
 |  | 1-3 | 92 | 51 | (55%) | 41 | (45%) | 0.873 |
 | M | 0 | 158 | 86 | (54%) | 72 | (46%) |  |
 |  | 1 | 1 | 1 | (100%) | 0 | (0%) | 1.000 |
 | G | 1 | 4 | 2 | (50%) | 2 | (50%) |  |
 |  | 2 | 113 | 60 | (53%) | 53 | (47%) |  |
 |  | 3 | 42 | 25 | (59%) | 17 | (41%) | 0.761 |
Prognostic Tumor Staging (UICC 7th edition) | ||||||||
 | Ia° |  | 19 | 12 | (63%) | 7 | (37%) |  |
 | Ib° |  | 16 | 8 | (50%) | 8 | (50%) |  |
 | IIa° |  | 28 | 14 | (50%) | 14 | (50%) |  |
 | IIb° |  | 13 | 8 | (61%) | 5 | (39%) |  |
 | IIIa° |  | 40 | 21 | (52%) | 19 | (47%) |  |
 | IIIb° |  | 20 | 10 | (50%) | 10 | (50%) |  |
 | IIIc° |  | 22 | 13 | (59%) | 9 | (41%) |  |
 | IV° |  | 1 | 1 | (100%) | 0 | (0%) | 0.931 |
Bone marrow micrometastasis | Â | Â | Â | Â | Â | Â | ||
 | Negative | 61 | 34 | (56%) | 27 | (44%) |  | |
 | Positive | 34 | 17 | (50%) | 17 | (50%) | 0.670 | |
CXCR7 status | Â | Â | Â | Â | Â | Â | ||
 | LN | Negative | 32 | 17 | (53%) | 15 | (47%) |  |
 |  | Positive | 20 | 9 | (45%) | 11 | (55%) | 0.776 |
 | Met | Negative | 6 | 4 | (67%) | 2 | (33%) |  |
 |  | Positive | 8 | 4 | (50%) | 4 | (50%) | 0.627 |
CXCR4 status | Â | Â | Â | Â | Â | Â | ||
 | PT | Negative | 17 | 12 | (71%) | 5 | (29%) |  |
 |  | Positive | 29 | 13 | (45%) | 16 | (55%) | 0.128 |